BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 36016388)

  • 1. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort.
    Zecca E; Rizzi M; Tonello S; Matino E; Costanzo M; Rizzi E; Casciaro GF; Manfredi GF; Acquaviva A; Gagliardi I; Calzaducca E; Mallela VR; D'Onghia D; Minisini R; Bellan M; Castello LM; Gavelli F; Avanzi GC; Patrucco F; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Sola D; Sainaghi PP
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.
    Rizzi M; Tonello S; Brinno C; Zecca E; Matino E; Cittone M; Rizzi E; Casciaro GF; D'Onghia D; Colangelo D; Minisini R; Bellan M; Castello LM; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Zavaglio F; Bergami F; Sola D; Sainaghi PP
    Front Immunol; 2023; 14():1185278. PubMed ID: 37545528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
    Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
    Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients.
    Hirama T; Akiba M; Shundo Y; Watanabe T; Watanabe Y; Oishi H; Niikawa H; Okada Y
    J Infect Chemother; 2022 Aug; 28(8):1153-1158. PubMed ID: 35599079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
    J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
    Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
    JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Int; 2022 Jan; 64(1):e15331. PubMed ID: 36331234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
    Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
    Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
    Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
    Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
    Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients.
    Cuadrado A; Del Barrio M; Fortea JI; Amigo L; San Segundo D; Rodriguez-Cundin MP; Rebollo MH; Fernandez-Santiago R; Castillo F; Achalandabaso M; Echeverri J; Anderson EJ; Rodríguez-Sanjuan JC; López-Hoyos M; Crespo J; Fábrega E
    Hepatol Commun; 2022 Jul; 6(7):1673-1679. PubMed ID: 35344281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
    Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
    Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
    Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
    J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.